liposomal irinotecan

Liposomal irinotecan is a nanoparticle-encapsulated formulation of the topoisomerase I inhibitor irinotecan, designed to enhance the delivery and metabolic conversion of the drug into its active form, SN-38, within tumor tissues. By utilizing a liposomal delivery system, the drug achieves a longer half-life and higher concentration of SN-38 in the tumor microenvironment compared to conventional irinotecan, while potentially mitigating systemic side effects. In the context of clinical research at Hebei Medical University Fourth Hospital, liposomal irinotecan is being evaluated as part of a neoadjuvant chemoradiation regimen for locally advanced rectal cancer. This specific application often involves UGT1A1 genotype-guided dosing to personalize treatment and manage potential toxicities such as neutropenia and diarrhea.

Brand names

OnivydeDuoenda

Other names

irinotecan liposomeirinotecan sucrosofate liposome injectionnanoliposomal irinotecan